A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
To determine the 16-week health economic outcomes of short-term, intensive lipid-lowering therapy with atorvastatin in patients with acute coronary syndrome (ACS) using unit costs from Spain. The total expected cost per patient and the cost per inpatient event avoided were compared for patients on atorvastatin 80 mg daily versus placebo. The analysis was based on clinical outcome data from the MIRACL study. Clinical outcomes measured in this analysis included: death, cardiac arrest, nonfatal myocardial infarction (MI), fatal MI, angina pectoris, stroke, congestive heart failure (CHF), and surgical or percutaneous coronary revascularizations. Unit costs for outcomes were values using 2001 Diagnosis Related Group (DRG) costs in Spain. The cost of a follow-up visit was added to the cost of each outcome in both groups. In the atorvastatin group, monitoring costs were also added. All direct medical costs were taken from the perspective of the Spanish National Health System during a 16-week period. The hospital cost in the atorvastatin group was <euro> 1,921 per patient, compared to <euro> 1,853 in the placebo group. The incremental cost per patient in the atorvastatin group was <euro> 67.47, corresponding to a cost per inpatient event avoided of <euro> 1,760. The cost of atorvastatin for 16 weeks was <euro> 128. Forty-seven percent of this cost of atorvastatin was offset by the cost savings obtained through the reduction of number of events in the atorvastatin group. In Spain, the intensive short-term use of atorvastatin in patients with ACS has a favorable cost-effectiveness. The direct cost of the drug was largely offset by the associated reduction in costs for treating fewer cardiovascular events.
Gómez-Gerique
Juan Antonio
JA
Clinic Biochemistry Department, Hospital Fundación Jiménez Díaz, Madrid, Spain.
Casciano
Roman
R
Stern
Lee
L
Rejas
Javier
J
D000208:Acute Disease; D000789:Angina, Unstable / Q000188:drug therapy* / Q000191:economics* / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D000069059:Atorvastatin; D001026:Coronary Artery Bypass; D017046:Cost Savings; D003362:Cost-Benefit Analysis; D003953:Diagnosis-Related Groups / Q000191:economics; D004311:Double-Blind Method; D017850:Economics, Pharmaceutical; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000191:economics* / Q000628:therapy; D010919:Placebos; D011758:Pyrroles / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012307:Risk Factors; D013030:Spain; D013577:Syndrome; D013997:Time Factors; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D010919:Placebos; D011758:Pyrroles; D000069059:Atorvastatin
N Engl J Med. 1995 Nov 16;333(20):1301-7
7566020
JAMA. 1998 May 27;279(20):1615-22
9613910
N Engl J Med. 1996 Oct 3;335(14):1001-9
8801446
JAMA. 1992 Jan 1;267(1):70-6
1727199
Lancet. 2001 Apr 7;357(9262):1063-8
11297956
Am J Med. 1984 Feb 27;76(2A):4-12
6702862
Med Care. 1994 Feb;32(2):150-63
8302107
JAMA. 2000 Aug 16;284(7):835-42
10938172
Am Heart J. 1999 May;137(5):S41-6
10220595
JAMA. 2002 Jun 19;287(23):3087-95
12069671
N Engl J Med. 1998 Nov 5;339(19):1349-57
9841303
Cardiovasc Surg. 1995 Dec;3(6):569-71
8745171
Am J Cardiol. 2001 Mar 15;87(6):771-4, A7
11249901
Z Kardiol. 1999 Aug;88(8):582-90
10506395
Rev Esp Cardiol. 2002 Apr;55(4):337-46
11975899
Am J Manag Care. 2000 Jun;6(6):693-700
10977478
Rev Esp Cardiol. 1996 Oct;49(10):753-8
9036478
Int J Cardiol. 2001 May;78(3):213-21; discussion 221-3
11376822
Lancet. 1999 Aug 28;354(9180):708-15
10475181
Pharmacoeconomics. 2003;21 Suppl 1:25-32
12648032
N Engl J Med. 1977 Mar 31;296(13):716-21
402576
N Engl J Med. 1998 May 21;338(21):1488-97
9599103
Hosp Formul. 1993 Apr;28(4):365-6, 371-3, 377-8
10125323
Am Heart J. 1998 Mar;135(3):523-31
9506340
Rev Esp Salud Publica. 2000 May-Jun;74(3):215-53
10918811
Lancet. 1994 Nov 19;344(8934):1383-9
7968073
JAMA. 2001 Jan 24-31;285(4):430-6
11242427
Rev Esp Cardiol. 1995;48 Suppl 1:94-8
7644830
BMJ. 1991 Aug 3;303(6797):276-82
1888927
J Invasive Cardiol. 1997 Mar;9 Suppl A:41A-46A
10762977
Arch Intern Med. 1992 Jul;152(7):1490-500
1627030
JAMA. 2001 Apr 4;285(13):1711-8
11277825